| Drug Name: | Galantamine (357-70-0) |
|---|---|
| PubChem ID: | 9651 |
| SMILES: | CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O |
| InchiKey: | ASUTZQLVASHGKV-JDFRZJQESA-N |
| Therapeutic Category: | Autonomic Agents, Central Nervous System Agents, Cholinergic Agents, Cholinesterase Inhibitors, Enzyme Inhibitors, Neurotransmitter Agents, Nootropic Agents, Parasympathomimetics, Peripheral Nervous System Agents |
| Molecular Weight (dalton) | : | 287.359 |
| LogP | : | 1.8503 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 41.93 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Anorexia | Cholinesterase precursor (P06276) | The asthenia and anorexia adverse effect of galantamine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
| Asthenia | Cholinesterase precursor (P06276) | The asthenia and anorexia adverse effect of galantamine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
| Diarrhoea | Cholinesterase precursor (P06276) | The diarrhoea adverse effect of galantamine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
| Dizziness | Cholinesterase precursor (P06276) | The dizziness adverse effect of galantamine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors. [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
| Nausea | Cholinesterase precursor (P06276) | The nausea and vomiting adverse effect of galantamine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors. [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
| Vomiting | Cholinesterase precursor (P06276) | The nausea and vomiting adverse effect of galantamine are dose related and largely depend on the degree of cholinesterase inhibition@after administration of cholinesterase inhibitors. [ ADR Type 1 ] | Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category